Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

About Portola Pharmaceuticals

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTLA
  • CUSIP:
Key Metrics:
  • Previous Close: $32.14
  • 50 Day Moving Average: $27.18
  • 200 Day Moving Average: $22.36
  • 52-Week Range: $15.68 - $33.28
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.45
  • P/E Growth: 0.00
  • Market Cap: $1.82B
  • Outstanding Shares: 56,543,000
  • Beta: 1.24
Profitability:
  • Net Margins: -1,072.67%
  • Return on Equity: -82.19%
  • Return on Assets: -66.51%
Debt:
  • Current Ratio: 6.36%
  • Quick Ratio: 6.36%
Additional Links:
Companies Related to Portola Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $32.00 (0.44% downside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017Citigroup Inc.Set Price TargetBuy$39.00View Rating Details
2/8/2017Oppenheimer Holdings, Inc.Set Price TargetHold$28.00View Rating Details
2/8/2017Cowen and CompanySet Price TargetBuy$40.00View Rating Details
1/11/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$22.00 -> $27.00View Rating Details
12/28/2016Morgan StanleyReiterated RatingOverweight$29.00View Rating Details
12/27/2016Credit Suisse GroupBoost Price TargetOutperform$20.00 -> $29.00View Rating Details
3/28/2016William BlairReiterated RatingBuyView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/24/2017        
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
Current Year EPS Consensus Estimate: $-4.92 EPS
Next Year EPS Consensus Estimate: $-3.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($1.18)($1.18)($1.18)
Q4 20161($1.09)($1.09)($1.09)
Q1 20172($1.19)($1.11)($1.15)
Q2 20172($1.12)($1.00)($1.06)
Q3 20172($1.17)($1.02)($1.10)
Q4 20172($1.13)($0.63)($0.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 87.38%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
DateHeadline
nasdaq.com logoPortola Pharmaceuticals Reaches Analyst Target Price (NASDAQ:PTLA)
www.nasdaq.com - February 22 at 7:30 PM
finance.yahoo.com logoPortola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28 (NASDAQ:PTLA)
finance.yahoo.com - February 21 at 5:28 PM
News IconFocusing on the Charts for Portola Pharmaceuticals Inc. (PTLA) - Midway Monitor (NASDAQ:PTLA)
midwaymonitor.com - February 18 at 8:05 AM
News IconPortola Pharmaceuticals, Inc. (PTLA): Essential Chart Information - NY Stock News (NASDAQ:PTLA)
nystocknews.com - February 18 at 8:05 AM
News IconPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Quarterly EPS At $-0.88 - Stock Observer (NASDAQ:PTLA)
www.thestockobserver.com - February 14 at 11:58 PM
News IconStock to Watch: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Baldwin Journal (NASDAQ:PTLA)
baldwinjournal.com - February 10 at 9:42 PM
marketexclusive.com logoPortola Pharmaceuticals Inc (NASDAQ:PTLA) Just Scored Twice In Quick Succession (NASDAQ:PTLA)
marketexclusive.com - February 10 at 3:10 AM
insidermonkey.com logoPortola Pharmaceuticals Inc (PTLA) Just Scored Twice In Quick Succession (NASDAQ:PTLA)
www.insidermonkey.com - February 9 at 10:08 PM
streetinsider.com logoPortola Pharma (PTLA) Informed by FDA No AdCom Planned for Betrixaban NDA (NASDAQ:PTLA)
www.streetinsider.com - February 9 at 2:32 AM
investopedia.com logoPortola Pharma Signs $150M Royalty Deal (PTLA) (NASDAQ:PTLA)
www.investopedia.com - February 9 at 2:32 AM
us.rd.yahoo.com logoFDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting (NASDAQ:PTLA)
us.rd.yahoo.com - February 9 at 2:32 AM
us.rd.yahoo.com logo8:02 am Portola Pharma announces that the FDA's Center for Drug Evaluation and Research has informed the Co that it does not plan to hold an Advisory Committee meeting for Portola's NDA for betrixaban (NASDAQ:PTLA)
us.rd.yahoo.com - February 9 at 2:32 AM
streetinsider.com logoPortola Pharma (PTLA) Informed by FDA No AdCom Planned for Betrixaban NDA - StreetInsider.com (NASDAQ:PTLA)
www.streetinsider.com - February 8 at 9:30 PM
investopedia.com logoPortola Pharmaceuticals Inks $150M Royalty Deal (NASDAQ:PTLA)
www.investopedia.com - February 8 at 9:30 PM
istreetwire.com logoEye Catching Stocks: Washington Prime Group Inc. (WPG), Portola Pharmaceuticals, Inc. (PTLA), HD Supply Holdings ... - iStreetWire (NASDAQ:PTLA)
istreetwire.com - February 7 at 8:39 AM
zacks.com logoPortola, HealthCare Royalty Partners Ink $150 Million Deal (NASDAQ:PTLA)
www.zacks.com - February 6 at 8:55 AM
streetinsider.com logoPortola Pharma (PTLA) Signs $150M Royalty Agreement with HealthCare Royalty Partners (NASDAQ:PTLA)
www.streetinsider.com - February 4 at 7:27 PM
streetinsider.com logoPortola Pharma (PTLA) Signs $150M Royalty Agreement with HealthCare Royalty Partners - StreetInsider.com (NASDAQ:PTLA)
www.streetinsider.com - February 3 at 8:14 PM
finance.yahoo.com logoPortola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa (NASDAQ:PTLA)
finance.yahoo.com - February 3 at 8:14 PM
finance.yahoo.com logo8:01 am Portola Pharma signs $150 mln royalty agreement with HealthCare Royalty Partners (NASDAQ:PTLA)
finance.yahoo.com - February 3 at 8:14 PM
thestreet.com logoPremarket Biotech Movers: Portola, Esperion, Medicines (NASDAQ:PTLA)
www.thestreet.com - February 3 at 8:14 PM
News IconWhat are Analysts Expecting for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Earnings? - Aiken Advocate (NASDAQ:PTLA)
aikenadvocate.com - February 1 at 2:15 AM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Portola Pharma, Tesaro, Sangamo Therapeutics, and Cerus (NASDAQ:PTLA)
www.bizjournals.com - January 31 at 9:14 PM
News IconTrading Radar: Checking Technicals for Portola Pharmaceuticals Inc. (PTLA) - Market Point (NASDAQ:PTLA)
mtptnews.com - January 31 at 1:04 AM
News IconInvestor Scope: Taking a Closer Look at Shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - The Tribune (NASDAQ:PTLA)
lakecitytribune.com - January 30 at 12:50 AM
News IconRSI Watch on Shares of Portola Pharmaceuticals Inc. (PTLA) - Market Point (NASDAQ:PTLA)
mtptnews.com - January 27 at 1:39 AM
News IconSwiss National Bank Has $1477000 Position in Achillion Pharmaceuticals Inc. (ACHN) (NASDAQ:PTLA)
vgtoday.net - January 26 at 2:21 AM
News IconCompany Focus: Zooming in on Shares of Portola Pharmaceuticals ... - The Tribune (NASDAQ:PTLA)
lakecitytribune.com - January 25 at 1:12 AM
News IconStock Update: Estimates & Target in Focus for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Aiken Advocate (NASDAQ:PTLA)
aikenadvocate.com - January 25 at 1:12 AM
News IconQuarterly EPS Of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Set ... - Stock Observer (NASDAQ:PTLA)
www.thestockobserver.com - January 25 at 1:12 AM
News IconEarnings in Full Force, Analysts Take Aim at Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Wall Street Beacon (NASDAQ:PTLA)
wsbeacon.com - January 25 at 1:12 AM
News IconFollowing the Average True Range Indicator for Portola Pharmaceuticals Inc. (PTLA) - Springdale Times (NASDAQ:PTLA)
springdaletimes.com - January 23 at 12:10 AM
News IconPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Bearish Target At $40 - Stock Observer (NASDAQ:PTLA)
www.thestockobserver.com - January 23 at 12:10 AM
News IconWill The Needle Move For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PTLA)
wsbeacon.com - January 18 at 12:45 AM
News IconPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Quarterly EPS Set At ... - Stock Observer (NASDAQ:PTLA)
www.thestockobserver.com - January 18 at 12:45 AM
istreetwire.com logoThree Movers to Watch for: DENTSPLY SIRONA Inc. (XRAY), Portola Pharmaceuticals, Inc. (PTLA), Autodesk, Inc ... - iStreetWire (NASDAQ:PTLA)
istreetwire.com - January 16 at 12:12 PM
fool.com logoWhy Portola Pharmaceuticals Crashed 56.4% In 2016 (NASDAQ:PTLA)
www.fool.com - January 14 at 5:02 AM
News IconPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Daily Sentiment Score At 0.16 - Stock Observer (NASDAQ:PTLA)
www.thestockobserver.com - January 13 at 1:01 AM
News IconPortola Pharmaceuticals Inc PTLA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PTLA)
www.bioportfolio.com - January 12 at 7:59 PM
fool.com logo3 Little-Known Pharmaceutical Companies to Put on Your Radar (NASDAQ:PTLA)
www.fool.com - January 12 at 7:59 PM
seekingalpha.com logoPortola Pharmaceuticals: Bleeding Out - Seeking Alpha (NASDAQ:PTLA)
seekingalpha.com - January 10 at 8:37 PM
fool.com logo2 Top Stocks in Biotech (NASDAQ:PTLA)
www.fool.com - January 10 at 8:37 PM
News IconEmerald Advisers Inc. PA Boosts Position in Portola Pharmaceuticals, Inc. (PTLA) (NASDAQ:PTLA)
itapunta.com - January 6 at 8:05 PM
News IconPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Broker Price Targets For The Coming Week (NASDAQ:PTLA)
xboxonezone.com - January 6 at 8:05 PM
News IconDaily Sentiment Score Of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0.201 - Stock Observer (NASDAQ:PTLA)
www.thestockobserver.com - January 5 at 3:26 PM
News IconPortola Pharmaceuticals, Inc. (PTLA) Position Raised by Sectoral Asset Management Inc (NASDAQ:PTLA)
perspectivabetica.com - January 5 at 1:21 AM
globenewswire.com logoPortola Pharmaceuticals to Webcast Corporate Update on January 10, 2017 - GlobeNewswire (press release) (NASDAQ:PTLA)
www.globenewswire.com - January 4 at 3:18 PM
marketexclusive.com logoAnalyst Upgrades – Portola Pharmaceuticals (NASDAQ:PTLA) Stock Gets Upgraded By Citigroup Inc. from Neutral to Buy (NASDAQ:PTLA)
marketexclusive.com - January 4 at 5:08 AM
News IconNext Weeks Broker Price Targets For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) (NASDAQ:PTLA)
larampadinapoli.com - January 4 at 12:06 AM
us.rd.yahoo.com logoPortola Pharma upgraded by Citigroup (NASDAQ:PTLA)
us.rd.yahoo.com - January 4 at 12:06 AM

Social

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 1-year target prices for Portola Pharmaceuticals' stock. Their predictions range from $27.00 to $40.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $32.00 in the next year.

When will Portola Pharmaceuticals announce their earnings?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, February, 24th 2017.

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Temasek Holdings Private Ltd (11.64%), Deerfield Management Co. (8.23%), FMR LLC (6.54%), State Street Corp (3.57%), Orbimed Advisors LLC (0.98%) and Pinnacle Associates Ltd. (0.97%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Fullerton Management Pte Ltd, Hollings Renton, John T Curnutte, Mardi Dier and William Lis.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co., Oxford Asset Management, FMR LLC, Pinnacle Associates Ltd., Guggenheim Capital LLC, Martingale Asset Management L P and Ladenburg Thalmann Financial Services Inc..

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, State Street Corp, Pacad Investment Ltd., Nicholas Investment Partners LP, Highland Capital Management LP, Ellington Management Group LLC and State Board of Administration of Florida Retirement System.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Portola Pharmaceuticals stock cost?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $32.14.

Portola Pharmaceuticals (NASDAQ:PTLA) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Earnings History Chart

Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Dividend History Chart

Dividend Payments by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Last Updated on 2/23/2017 by MarketBeat.com Staff